# ITC

# Mixed bag; FMCG continues to shine

ITC delivered a mixed bag result in a challenging environment. Most OOH consumption categories were impacted in 2Q, and the cigarettes category was not left out. Cigarette net revenue/vol/EBIT clocked -14/-12/-16% growth as compared to our expectation of -8/-10/-8% YoY. FMCG revenue growth was at 15% (HSIE 12.5%), better than Nestle/Britannia (10/11% YoY). EBIT/EBITDA margin was at 6.7/9.7% (HSIE 3.6/7%). Localised lockdowns impacted the recovery in August to mid-Sep for cigarettes, which was witnessed in June-July. Key markets like Karnataka, Maharashtra, and Tamil Nadu were weak with COVID impact. Cigarette mix was also unfavourable and impacted margin. Volume recovery at the end of the quarter is a positive sign. FMCG continues to shine, and ITC is capitalising the high demand for health, hygiene and packaged food products. We cut our EPS estimate for FY21 by 3% while maintaining it for FY22/FY23. We value ITC on SoTP and maintain target price at Rs 236 (implied P/E of 18x P/E Sep-22E EPS). Maintain BUY.

- FMCG remains strong: Net revenue for ITC grew by 1% YoY (+6% in 2QFY20 and -17% in 1QFY21) vs. the expectation of 4% YoY decline. Cigarette (net)/Hotels/Paper declined 14/81/7% YoY, while FMCG/Agri business saw 18/13% YoY growth. South, metros and large towns were the worst impacted in 2Q. Cigarette demand has improved in most regions except the west, where recovery is slow. Cigarette volume mix is also expected to improve in 2HFY21. FMCG saw comparable growth of 18% YoY, with 25% YoY growth in staples, convenience foods and health & hygiene (75% of the portfolio). Essential products are normalising now while discretionary products are seeing acceleration. E-comm (2x YoY) and GT continued their growth trajectory while MT remained under pressure. ITC gained market share across the portfolio (Aashirvaad, Yippee, Savlon).
- Margins under pressure: Gross margin fell by 180bps YoY to 60.4% (+21bps in 2QFY20 and -555bps in 1QFY21) vs the expectation of contraction of 75bps YoY. Employee/other expenses grew 5/15% YoY, leading to an EBITDAM dip of 453bps YoY (+112bps in 2QFY20 and -1,184bps in 1QFY21). Overall EBITDA declined by 11% YoY. Cigarette (adjusting for excise duty on inventory)/Agri/Paper EBIT margins dipped by 135/84/9bps YoY while Hotels clocked an EBIT loss of Rs 1.8bn. FMCG EBITDA/EBIT margin expanded by 300/391bps YoY to 9.7/6.7%. PBT declined by 11% YoY while PAT declined by 20% YoY (lower tax rate in the base quarter).
- Press release takeaways: (1) Cigarette margin was impacted by higher impact in states with a higher premium mix; (2) ITC saw substantial market share gains within capsules; (3) e-comm revenue salience stood at 5%; (4) aggressive cost rationalisation led to savings of 50% of cash fixed costs in hotels; (5) Saylon remains on course to become a Rs 10-bn brand in FY21.

**Quarterly/Annual Financial summary** 

YE Mar (Rs mn)	2QFY21	2QFY20	YoY (%)	1QFY21	<i>QoQ</i> (%)	FY20	FY21E	FY22E	FY23E
Net Sales	119,768	118,715	0.9	95,018	26.0	494,041	485,694	546,001	590,055
EBITDA	40,606	45,624	(11.0)	26,466	53.4	192,602	172,436	203,298	218,584
APAT	32,324	40,231	(19.7)	23,428	38.0	152,275	136,299	159,094	170,441
Diluted EPS (Rs)	2.6	3.3	(19.8)	1.9	37.8	12.4	11.1	12.9	13.9
P/E (x)						14.0	15.7	13.4	12.5
EV / EBITDA (x)						9.2	10.3	8.5	7.8
RoCE (%)						45.7	39.0	45.6	47.5

Source: Company, HSIE Research

# BUY

T/T/T/T/	
NIFTY	12,264
Target Price	Rs 236
CMP (as on 06 Nov 2020)	Rs 174

CMD (-- -- 06 May 2020)

KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	Rs 236	Rs 236
	FY21E	FY22E
EPS %	-3%	0%

#### KEY STOCK DATA

Bloomberg code	ITC IN
No. of Shares (mn)	12,305
MCap (Rs bn) / (\$ mn)	2,140/28,864
6m avg traded value (Rs mn)	5,529
52 Week high / low	Rs 266/135

#### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	(11.0)	6.1	(33.4)
Relative (%)	(21.1)	(26.1)	(37.0)

#### SHAREHOLDING PATTERN (%)

	June-20	Sep-20
Promoters	0.00	0.00
FIs & Local MFs	42.09	43.54
FPIs	14.60	12.96
Public & Others	43.31	43.50
Pledged Shares	0.00	0.00

Source : BSE

Pledged shares as % of total shares

#### Varun Lohchab

varun.lohchab@hdfcsec.com +91-22-6171-7334

## Naveen Trivedi

naveen.trivedi@hdfcsec.com +91-22-6171-7324

## Aditya Sane

aditya.sane@hdfcsec.com +91-22-



## **HSIE Results Daily**



#### Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

#### Disclaimer

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

## **HDFC** securities

#### **Institutional Equities**

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com